1. ���ϴ�ѧ������һҽԺ
2. �������ϴ�ѧҽѧԺ��һ����ҽԺƤ����

����ͷ���������硢��״��������硢��������ȱ�ݲ�������͵��������������о�ȡ��һ���Ľ�չ���⽫��Ƥ���Բ���Ԥ������Ӱ�죬��ýϺõ�Ԥ��Ч�������ҿ��Լ���4�ֲ�����Ⱦ���¼�����ҽ�Ƹ�����Ϊ�ˣ���һЩ�µ�����ͷ����������ʹ�״������������Ч�Ͱ�ȫ�������Լ����̲�����͵��������������½�չ���и�����

Progress has been made in the research of vaccines against human papillomavirus ��HPV��, herpes zoster virus ��HZV��, human immunodeficiency virus ��HIV�� and herpes simplex virus ��HSV��, which will benefit the prevention of some dermatoses and venereal diseases, and reduce the healthcare burden associated with diseases caused by the four viruses. This review describes recent advances in studies on efficacy and safety of vaccines against HPV and HZV, and in development of vaccines against HIV and HSV.

[1] FUTURE �� Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 2007, 356(19):1915-1927. [2] FUTURE �� Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis,2007, 196(10):1438-1446. [3] Stanley M. Prophylactic HPV vaccines. J Clin Pathol,2007, 60(9):961-965. [4] Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis, 2007, 11��Suppl 2��: S17-S25. [5] Morris SK, Nguyen CK. The human papillomavirus vaccine in Canada. Can J Public Health, 2008, 99��2��:114-116. [6] Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wetterndorff M, Stanberry LR, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005;192:20 99-107. [7]. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cellmediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:13 36-44. [8]. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JK. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005;191:200 2-7. [9]. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE,Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:22;71-84. [10] John W. Gnann, Jr. Vaccination to Prevent Herpes Zoster in Older Adults . The Journal of Pain, 2008, 9(1 ):S31-S36. [11] Peng-jun Lua, Gary L. Eulera, Aisha O. Jumaanb et al. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniors. Vaccine 27 (2009) 882–887. [12]���й���ѧԺ������ѧ��ҽѧѧ��. �����ҹ����̲������з����ԵĽ���. �й���ѧԺԺ��, 2006, 21: 391 - 394. [13]��McMichael AJ. H IV vaccines. Annul Rev Immunol, 2006,24: 227 - 255. [14] Scheid JF, Mouquet H, Feldhahn N, Seaman MS et al. Broad diversity of neutralizing antibodies isolated from memory B cNature. 2009 Apr 2;458(7238):584-5. [15] Us D. Herpes simp lex virus vaccine studies: from past to p resent. Mikrobiyol Bul, 2006, 40 (4) : 413-433��ells in HIV-infected individuals. [16] Parsania M, Bamdad T, Hassan ZM, et al. Evaluation of apoptotic and anti-apoptotic genes on efficacy of DNA vaccine encoding glycoprotein B of Herpes Simplex Virus type 1. Immunol Lett. 2009 Dec 21. [Epub ahead of print]. [17] Bernstein DI, Farley N, Bravo FJ, et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine. 2009 Oct 24. [Epub ahead of print].